title: Novel immunotherapy for adult T-cell leukemia/lymphoma: Targeting aurora kinase A.
abstract: Adult T-cell leukemia/lymphoma is caused by infection with HTLV-1, following a long latent period. Immunotherapy targeting Aurora kinase A, a tumor-associated antigen over-expressed in adult T-cell leukemia/lymphoma, holds great therapeutic potential. We review the evidence in favor of a therapeutic strategy combining vaccination and TCR-gene transfer against this target.
authors.affiliation: Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime University , Toon, Ehime, Japan.
authors.forename: Nicholas Paul
authors.initials: NP
authors.lastname: Casey
authors.affiliation: Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime University , Toon, Ehime, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Fujiwara
authors.affiliation: Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime University , Toon, Ehime, Japan.
authors.forename: Toshiki
authors.initials: T
authors.lastname: Ochi
authors.affiliation: Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime University , Toon, Ehime, Japan.
authors.forename: Masaki
authors.initials: M
authors.lastname: Yasukawa
keywords: Adult T-cell leukemia/lymphoma; T-cell receptor gene; aurora kinase A; engineered T cell; immunotherapy